Clinical Trial

Vitamin A and D Supplementation in Allogeneic HCT

Study acronym: VitaStem
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-12.
Trial Details
NCT Number NCT06508099
Lead Sponsor St. Petersburg State Pavlov Medical University
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloprolipherative Neoplsm, Non-hodgkin Lymphoma
Enrollment 220 participants
Start Date 2024-05-15
Primary Completion 2026-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2024-07-31